Bleeding and thrombotic disorders result from imbalances in coagulation or fibrinolysis, respectively. Inhibitors from the serine protease inhibitor (serpin) family have a key role in regulating these physiological events, and thus stand out as potential therapeutic targets for modulating fibrin clot formation or dismantling. Here, we review the diversity of serpin-targeting strategies in the area of hemostasis, and detail the suggested use of modified serpins and serpin inhibitors (ranging from small-molecule drugs to antibodies) to treat or prevent bleeding or thrombosis.
CITATION STYLE
Bianchini, E. P., Auditeau, C., Razanakolona, M., Vasse, M., & Borgel, D. (2021, January 7). Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders. Frontiers in Cardiovascular Medicine. Frontiers Media S.A. https://doi.org/10.3389/fcvm.2020.622778
Mendeley helps you to discover research relevant for your work.